Telephone
1.858.836.5000
Address
9001 Spectrum Center Boulevard San Diego, CA 92123
Description
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 21.14 - 34.27
Trade Value (12mth)
US$11,910,374.00
1 week
1.36%
1 month
18.64%
YTD
29.11%
1 year
-3.5%
All time high
40.790000915527344
EPS 3 yr Growth
42.000%
EBITDA Margin
31.90%
Operating Cashflow
$693m
Free Cash Flow Return
14.00%
ROIC
18.10%
Interest Coverage
22.20
Quick Ratio
1.80
Shares on Issue (Fully Dilluted)
1474m
HALO Sector
Healthcare
Next Company Report Date
01-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.41
Date | Announcements |
---|---|
10 May 24 |
Update - Dividend/Distribution - RMD
×
Update - Dividend/Distribution - RMD |
03 May 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
29 April 24 |
Form 10-Q for the Quarter ended March 31, 2024
×
Form 10-Q for the Quarter ended March 31, 2024 |
26 April 24 |
ResMed Announces Results for the Third Quarter of FY2024
×
ResMed Announces Results for the Third Quarter of FY2024 |
26 April 24 |
Dividend/Distribution - RMD
×
Dividend/Distribution - RMD |
05 April 24 |
ResMed to Report Third Quarter Fiscal 2024 Results
×
ResMed to Report Third Quarter Fiscal 2024 Results |
04 April 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
04 March 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
09 February 24 |
Update - Dividend/Distribution - RMD
×
Update - Dividend/Distribution - RMD |
05 February 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
29 January 24 |
Form 10-Q for the Quarter ended December 31, 2023
×
Form 10-Q for the Quarter ended December 31, 2023 |
25 January 24 |
ResMed Announces Results for the Second Quarter of FY2024
×
ResMed Announces Results for the Second Quarter of FY2024 |
25 January 24 |
Dividend/Distribution - RMD
×
Dividend/Distribution - RMD |
05 January 24 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
04 January 24 |
ResMed to Report Second Quarter Fiscal 2024 Results
×
ResMed to Report Second Quarter Fiscal 2024 Results |
05 December 23 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
21 November 23 |
ResMed Inc. Amended and Restated Bylaws
×
ResMed Inc. Amended and Restated Bylaws |
21 November 23 |
Form 8K
×
Form 8K |
10 November 23 |
ResMed Adopts New Operating Model
×
ResMed Adopts New Operating Model |
10 November 23 |
Update - Dividend/Distribution - RMD
×
Update - Dividend/Distribution - RMD |
03 November 23 |
Statement of CDIs on issue - RMD
×
Statement of CDIs on issue - RMD |
30 October 23 |
FORM 10Q for Qtr ended September, 2023
×
FORM 10Q for Qtr ended September, 2023 |
27 October 23 |
ResMed Announces Results for the First Quarter of FY2024
×
ResMed Announces Results for the First Quarter of FY2024 |
27 October 23 |
Dividend/Distribution - RMD
×
Dividend/Distribution - RMD |
06 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.